NO20064933L - Makrosykliske forbindelser som inhibitorer av viral replikasjon - Google Patents

Makrosykliske forbindelser som inhibitorer av viral replikasjon

Info

Publication number
NO20064933L
NO20064933L NO20064933A NO20064933A NO20064933L NO 20064933 L NO20064933 L NO 20064933L NO 20064933 A NO20064933 A NO 20064933A NO 20064933 A NO20064933 A NO 20064933A NO 20064933 L NO20064933 L NO 20064933L
Authority
NO
Norway
Prior art keywords
methods
inhibitors
viral replication
macrocyclic compounds
compound
Prior art date
Application number
NO20064933A
Other languages
English (en)
Norwegian (no)
Inventor
Steven Wade Andrews
Lawrence M Blatt
Steven Mark Wenglowsky
Yutong Jiang
April Layne Kennedy
Kevin Ronald Condroski
John Anthony Josey
Peter J Stengel
George Andrew Doherty
Benjamin T Woodard
Machender R Madduru
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of NO20064933L publication Critical patent/NO20064933L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20064933A 2004-03-30 2006-10-27 Makrosykliske forbindelser som inhibitorer av viral replikasjon NO20064933L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55816104P 2004-03-30 2004-03-30
US56241804P 2004-04-14 2004-04-14
US61246004P 2004-09-22 2004-09-22
US61238104P 2004-09-22 2004-09-22
PCT/US2005/010494 WO2005095403A2 (fr) 2004-03-30 2005-03-29 Composes macrocycliques inhibiteurs de replication virale

Publications (1)

Publication Number Publication Date
NO20064933L true NO20064933L (no) 2006-12-15

Family

ID=35005653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064933A NO20064933L (no) 2004-03-30 2006-10-27 Makrosykliske forbindelser som inhibitorer av viral replikasjon

Country Status (16)

Country Link
EP (1) EP1749007A2 (fr)
JP (1) JP4950026B2 (fr)
AP (1) AP2006003763A0 (fr)
AR (1) AR050321A1 (fr)
AU (1) AU2005228894B9 (fr)
BR (1) BRPI0509467A (fr)
CA (1) CA2560897C (fr)
CU (1) CU23787B7 (fr)
EA (1) EA012389B1 (fr)
EC (1) ECSP066959A (fr)
GE (1) GEP20104926B (fr)
IL (1) IL177917A0 (fr)
MA (1) MA28548B1 (fr)
NO (1) NO20064933L (fr)
NZ (1) NZ549697A (fr)
WO (1) WO2005095403A2 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL1863833T3 (pl) 2005-03-08 2014-03-31 Boehringer Ingelheim Int Sposób otrzymywania związków makrocyklicznych
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
US20090148407A1 (en) * 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
BRPI0614242A2 (pt) 2005-07-29 2011-03-15 Medivir Ab inibidores macrocìclicos do vìrus da hepatite c, combinação e composição farmacêutica compreendendo os mesmos, bem como uso e processo para a preparação dos referidos inibidores
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT1966130E (pt) 2005-12-23 2014-01-30 Zealand Pharma As Compostos miméticos de lisina modificados
EP2049474B1 (fr) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
BRPI0714343A2 (pt) 2006-07-13 2013-03-19 Achillion Pharmaceuticals Inc peptÍdeos de 4-amino-4-oxobutanoil como inibidores de replicaÇço viral
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2357494T3 (es) * 2006-11-16 2011-04-27 Bristol-Myers Squibb Company Péptidos macrocíclicos como inhibidores de la hepatitis c.
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK2468724T3 (en) 2006-12-21 2016-02-22 Zealand Pharma As Synthesis of pyrrolidine compounds
AU2008205116A1 (en) * 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis C protease inhibitors
WO2008096002A1 (fr) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Phosphonates et amidophosphates macrocycliques inhibiteurs du vhc
CA2679377A1 (fr) 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Peptides substitues par une amine tertiaire utiles comme inhibiteurs de la replication du virus de l'hepatite c
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090155209A1 (en) 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
WO2009005677A2 (fr) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Composés antiviraux
KR101596524B1 (ko) * 2007-06-29 2016-02-22 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
AR067180A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Compuestos antivirales
SE531698C2 (sv) 2007-07-12 2009-07-07 Respiratorius Ab Nya bronkdilaterande a,b-omättade amider
NZ586231A (en) 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
AU2008340261C1 (en) 2007-12-21 2015-12-10 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
BRPI0821836A2 (pt) * 2007-12-24 2015-06-16 Tibotec Pharm Ltd Indóis macrocíclicos como inibidores do vírus da hepatite c
BRPI0909205A2 (pt) * 2008-04-11 2015-08-11 Hoffmann La Roche Complexos de rutênio como catalizadores para reações de metátese
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
KR101647520B1 (ko) * 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MY152824A (en) 2008-09-17 2014-11-28 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5723783B2 (ja) 2008-12-10 2015-05-27 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製の阻害剤としての新しい４−アミノ−４−オキソブタノイルペプチド
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
WO2010075517A2 (fr) 2008-12-23 2010-07-01 Pharmasset, Inc. Analogues de nucléoside
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
HUE031738T2 (en) 2009-02-27 2017-07-28 Janssen Pharmaceuticals Inc Amorphous salts of the HCV macrocyclic inhibitor
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
ME01718B (me) 2009-07-07 2014-09-20 Boehringer Ingelheim Int Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
EP2483273A4 (fr) * 2009-09-28 2013-05-01 Hoffmann La Roche Nouveaux inhibiteurs macrocycliques de réplication du virus de l'hépatite c
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US8785487B2 (en) 2010-01-25 2014-07-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2455068A1 (fr) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Composition pharmaceutique pour le traitement d'infections par VHC
US9302989B2 (en) 2010-11-15 2016-04-05 Abbvie Inc. NAMPT and rock inhibitors
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
CA2822556A1 (fr) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Inhibiteurs macrocycliques de serine protease d'hepatite c
WO2012109398A1 (fr) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
KR20150023722A (ko) 2012-06-12 2015-03-05 애브비 인코포레이티드 피리디논 및 피리다지논 유도체
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014070964A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014137869A1 (fr) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2970195B1 (fr) 2013-03-14 2017-08-02 Achillion Pharmaceuticals, Inc. Processus de production de sovaprevir
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
AU2014227849A1 (en) 2013-03-15 2015-10-01 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
EP1337550B1 (fr) * 2000-11-20 2006-05-24 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (fr) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques qui agissent contre le virus de l'hepatite c
CA2369970A1 (fr) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
CA2370396A1 (fr) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2003099316A1 (fr) * 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
NZ546347A (en) * 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
WO2005073195A2 (fr) * 2004-01-30 2005-08-11 Medivir Ab Inhibiteurs de la ns-3 serine protease du vhc

Also Published As

Publication number Publication date
IL177917A0 (en) 2006-12-31
GEP20104926B (en) 2010-03-25
JP2007531749A (ja) 2007-11-08
JP4950026B2 (ja) 2012-06-13
EP1749007A2 (fr) 2007-02-07
AP2006003763A0 (en) 2006-10-31
EA200601467A1 (ru) 2007-06-29
CU20090209A7 (es) 2011-04-26
AU2005228894B2 (en) 2011-08-25
AU2005228894A1 (en) 2005-10-13
EA012389B1 (ru) 2009-10-30
NZ549697A (en) 2009-12-24
WO2005095403A2 (fr) 2005-10-13
AU2005228894B9 (en) 2011-10-13
CU23787B7 (es) 2012-03-15
CA2560897C (fr) 2012-06-12
AR050321A1 (es) 2006-10-18
BRPI0509467A (pt) 2007-09-11
ECSP066959A (es) 2006-12-20
CA2560897A1 (fr) 2005-10-13
MA28548B1 (fr) 2007-04-03
WO2005095403A3 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
NO20064933L (no) Makrosykliske forbindelser som inhibitorer av viral replikasjon
NO20080875L (no) Nye makrocykliske inhibitorer av hepatitt C virus replikasjon
NO20062089L (no) Makrosykliske karboksylsyrer og acylsulfonamider som inhibitorer av HCV-replikasjon
WO2007047146A3 (fr) Inhibiteurs de réplication virale
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
EA201071034A1 (ru) Новые макроциклические ингибиторы репликаций вируса гепатита с
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
NO20062101L (no) Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
WO2008005511A3 (fr) Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
NO20072286L (no) Hemming av HCV NS3-NS4A-protease
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005077969A3 (fr) Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
CY1109748T1 (el) Κινοξαλινυλ μακροκυκλικοι αναστολεις πρωτεασης σερινης ηπατιτιδας c
WO2009053828A3 (fr) Inhibiteurs p3-hydroxyamino macrocycliques des sérine protéases de l'hépatite c
WO2005035525A3 (fr) Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc)
TW200611905A (en) Macrocyclic compounds as inhibitors of viral replication
CU23602A3 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
UA84579C2 (ru) Макроциклические карбоновые кислоты и ацилсульфонамиды как ингибиторы репликации вируса гепатита с

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application